ACE2 and COVID-19: Using antihypertensive medications and pharmacogenetic considerations

Eric M. Snyder, Bruce D. Johnson

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations

Abstract

COVID-19 utilizes the ACE2 pathway as a means of infection. Early data on COVID-19 suggest heterogeneity in the severity of symptoms during transmission and infection ranging from no symptoms to death. The source of this heterogeneity is likely multifaceted and may have a genetic component. Demographic and clinical comorbidities associated with the severity of infection suggest that possible variants known to influence the renin-angiotensin-aldosterone (RAAS) system pathway (particularly those that influence ACE2) may contribute to the heterogenous infection response. ACE2 and Ang(1-7) (the product of ACE2) seem to have a protective effect on the pulmonary and cardiac systems. Hypertension medication modulation, may alter ACE2 and Ang(1-7), particularly in variants that have been shown to influence RAAS system function, which could be clinically useful in patients with COVID-19.

Original languageEnglish (US)
Pages (from-to)695-703
Number of pages9
JournalPharmacogenomics
Volume21
Issue number10
DOIs
StatePublished - Jul 2020

Keywords

  • ACE-inhibition
  • ACE2
  • COVID-19
  • angiotensin-receptor blockade
  • angiotensinogen
  • cardiac dysfunction
  • coronavirus
  • genomics
  • renin
  • respiratory failure

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Pharmacology

Fingerprint Dive into the research topics of 'ACE2 and COVID-19: Using antihypertensive medications and pharmacogenetic considerations'. Together they form a unique fingerprint.

Cite this